Two phase I clinical trials separately investigating SP-2577, a lysine-specific histone demethylase 1 inhibitor, and TK216, a small molecule that interferes with EWS/FLI and RNA helicase A interaction, are ongoing in relapsed/refractory ES patients (NCT03600649 and NCT02657005). Here, DHX9 is linked to Ewing sarcoma.